Safety Data From the Phase II JULIET Trial in DLBCL

November 28, 2018
Peter Borchmann, MD

Peter Borchmann, MD, discusses the safety signals seen so far in the phase II JULIET trial investigating tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment option for patients with diffuse large B-cell lymphoma.

Peter Borchmann, MD, a professor in the department of internal medicine at the University Hospital of Cologne, discusses the safety signals seen so far in the phase II JULIET trial investigating tisagenlecleucel (Kymriah), a chimeric antigen receptor (CAR) T-cell therapy, as a treatment option for patients with diffuse large B-cell lymphoma (DLBCL).

With CAR T-cell therapies, cytokine relapse syndrome (CRS) and neurological events are of special interest in regard to safety. In this study, 58% of patients experienced CRS of some grade, but only 22% of patients experienced grade 3 or greater CRS.